Table 2 Selected patient demographic and baseline characteristics by HER2 mRNA expression and treatment arm
Characteristic | HER2 mRNA < median (n = 58) | HER2 mRNA ≥ median (n = 58) | ||||
|---|---|---|---|---|---|---|
HT | T-DM1 | Total | HT | T-DM1 | Total | |
(n = 32) | (n = 26) | (n = 58) | (n = 29) | (n = 29) | (n = 58) | |
Median age, years (range) | 52.5 | 54.5 | 53.5 | 51.0 | 54.0 | 53.0 |
(36 to 72) | (32 to 74) | 32 to 74 | (33 to 75) | (27 to 82) | (27 to 82) | |
World region, % | ||||||
US | 34.4 | 38.5 | 36.2 | 24.1 | 27.6 | 25.9 |
Non-US | 65.6 | 61.5 | 63.8 | 75.9 | 72.4 | 74.1 |
Race, % a | ||||||
White | 81.3 | 80.8 | 81.0 | 86.2 | 72.4 | 79.3 |
American Indian or Alaskan native | 9.4 | 7.7 | 8.6 | 6.9 | 6.9 | 6.9 |
Black | 6.3 | 0.0 | 3.4 | 3.4 | 6.9 | 5.2 |
Other or not available | 3.1 | 11.5 | 6.9 | 3.4 | 13.8 | 8.6 |
ECOG PS, % | ||||||
0 | 62.5 | 80.8 | 70.7 | 57.1 | 69.0 | 63.2 |
1 | 37.5 | 19.2 | 29.3 | 42.9 | 31.0 | 36.8 |
HER2 status by central laboratory, % | ||||||
HER2-positive | 71.9 | 73.1 | 72.4 | 100.0 | 100.0 | 100.0 |
Normal | 28.1 | 26.9 | 27.6 | 0.0 | 0.0 | 0.0 |
ER/PR status, % a | ||||||
ER-positive and/or PR-positive | 65.6 | 57.7 | 62.1 | 48.3 | 44.8 | 46.6 |
ER-negative and PR-negative | 28.1 | 42.3 | 34.5 | 48.3 | 51.7 | 50.0 |
ER and PR unknown | 6.3 | 0 | 3.4 | 3.4 | 3.4 | 3.4 |
Number of distinct sites involved a | ||||||
1 to 2 | 43.8 | 30.8 | 37.9 | 50.0 | 44.8 | 47.4 |
>2 | 56.3 | 69.2 | 62.1 | 50.0 | 55.2 | 52.6 |